Traditional Chinese herbal medicine for treating novel coronavirus (COVID-19) pneumonia: protocol for a systematic review and meta-analysis

Yuxi Li, Xiaobo Liu, Liuxue Guo, Juan Li, Dongling Zhong, Yonggang Zhang, Mike Clarke, Rongjiang Jin, Yuxi Li, Xiaobo Liu, Liuxue Guo, Juan Li, Dongling Zhong, Yonggang Zhang, Mike Clarke, Rongjiang Jin

Abstract

Background: A new type of coronavirus, novel coronavirus (COVID-19), is causing an increasing number of cases of pneumonia and was declared a Public Health Emergency of International Concern by the World Health Organization on 30 January 2020. The virus first appeared in Wuhan, China, in late December 2019, and traditional Chinese herbal medicine is being used for its treatment. This systematic review and meta-analysis will assess studies of the effects of traditional Chinese herbal medicine in COVID-19 pneumonia.

Methods: We will search electronic databases including PubMed, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), Chinese Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), Chinese Science and Technology Periodical Database (VIP), and Wanfang database using keywords related to COVID-19 and traditional Chinese herbal medicine. Reference lists of relevant trials and reviews will be searched. We will manually search gray literature, such as conference proceedings and academic degree dissertations, and trial registries. Two independent reviewers will screen studies (XL and DZ), extract data (YL and LG), and evaluate risk of bias (YL and DZ). Data analysis will be conducted using the Review Manager software (version 5.3.5) and R software (version 3.6.1). Statistical heterogeneity will be assessed using a standard chi-square test with a significance level of P < 0.10. Biases associated with study size (e.g., publication bias) will be investigated using funnel plots, Egger's test and Begg's test, and Trim and Fill analysis.

Discussion: This study will provide a high-quality synthesis of the effects of traditional Chinese herbal medicine for COVID-19. The use of traditional Chinese herbal medicine for treatment or prevention of these novel viral infections affecting the pneumonia will be investigated.

Systematic review registration: PROSPERO registration number: CRD42020168004.

Keywords: COVID-19; Coronavirus; Meta-analysis; Pneumonia; Systematic review; Traditional Chinese herbal medicine emerging infectious diseases.

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Novel Coronavirus (2019-nCoV) Situation Report-1 [].
    1. The 2019-nCoV Outbreak Joint Field Epidemiology Investigation Team. Li Q. An Outbreak of NCIP (2019-nCoV) Infection in China — Wuhan, Hubei Province. China CDC Weekly 2020. 2019;2(5):79–80.
    1. Wenjie T, Xiang Z, Xuejun M, Wenling W, Peihua N, Wenbo X, George FG, Guizhen W. A novel coronavirus genome identified in a cluster of pneumonia cases — Wuhan, China 2019−2020. China CDC Weekly. 2020;2(4):61–62.
    1. Tan WJZX, Ma XJ. A novel coronavirus genome identified in a cluster of pneumonia cases-Wuhan, China 2019-2020. China CDC Weekly. 2020;2:61–62.
    1. Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. A novel coronavirus emerging in China—key questions for impact assessment. New England Journal of Medicine. 2020.
    1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;S0140-6736(0120):30183–30185.
    1. Editorials: Stop the Wuhan coronavirus. nature 2020, 557.
    1. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020.
    1. Nishiura H, S-m J, Linton NM, Kinoshita R, Yang Y, Hayashi K, Kobayashi T, Yuan B, Akhmetzhanov AR. The extent of transmission of novel coronavirus in Wuhan, China, 2020. J Clin Med. 2020;9(330).
    1. Wu P, Hao X, Lau EHY, Wong JY, Leung KSM, Wu JT, Cowling BJ, Leung GM: Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020. Euro Surveill 2020, 25(3):10.2807/1560-7917.ES.2020.2825.2803.2000044.
    1. Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, Xing F, Liu J, Yip CC-Y, Poon RW-S et al: A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020:S0140-6736(0120)30154-30159.
    1. Lippi G, Plebani M. The novel coronavirus (2019-nCoV) outbreak: think the unthinkable and be prepared to face the challenge. Diagnosis. .
    1. Novel Coronavirus(2019-nCoV) Situation Report-56 [].
    1. Ma Q, Yu Q, Xing X, Liu S, Shi C, Luo J. San Wu Huangqin decoction, a Chinese herbal formula, inhibits influenza a/PR/8/34 (H1N1) virus infection in vitro and in vivo. Viruses. 2018;10(3):117. doi: 10.3390/v10030117.
    1. Ding Y, Zeng L, Li R, Chen Q, Zhou B, Chen Q, Cheng P, Wang Y, Zheng J, Yang Z. The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function. Bmc Complementary & Alternative Medicine. 17(1):130.
    1. Du H, Zhou H, Wan H, Yang J, Lu Y, He Y, Wan H. Antiviral effects and mechanisms of Yinhuapinggan granule against H1N1 influenza virus infection in RAW264.7 cells. Inflammopharmacology. 2018;26(6):1455–1467. doi: 10.1007/s10787-018-0457-1.
    1. Liu D, Liang B, Huang L, Fang Y, Zheng J, Wang G, Zhang S, Lin W, Huang T, Cai Q: Clinical observation on the preventive effect of kangdu bufei decoction on acute severe respiratory syndrome. Chinese Journal of Integrated Traditional and Western Medicine 2004, 24(685-688).
    1. Tong X, Li A, Zhang Z, Duan J, Chen X, Hua C, Zhao D, Xu Y, Shi X, Li P. TCM treatment of infectious atypical pneumonia--a report of 16 cases. J Tradit Chin Med. 2004;24(4):266–269.
    1. Liu B, He L, Liang Z, Tong X, Hu J, Ni Q, Liu X, Jiao Q, Xie Y, Li P. Effect of Chinese herbal medicine on adrenal glucocorticoids in SARS. China Journal of Chinese Materia Medica. 2005;30(23):1874–1877.
    1. Hai X. Clinical experience of SARS treatment in Guangdong province. Tianjin Journal of Traditional Chinese. 2003;20(3):24–25.
    1. Jia J. Traditional Chinese Medicine integrated western medicine for SARS. Tianjin Journal of Traditional Chinese. 2003;20(3):28–30.
    1. A patient diagnosed with 2019-nCoV pneumonia was discharged from Beijing [].
    1. One patient with 2019-nCoV pneumonia was discharged today in Beijing, with a total of two discharged [].
    1. Pneumonitis Diagnosis and Treatment Program for New Coronavirus Infection (Trial Version 4). In. Edited by The General Office of the National Health and Health Commission of China, Office of the State Administration of Traditional Chinese Medicine. Beijing; 2020.
    1. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;349(1):g7647. doi: 10.1136/bmj.g7647.
    1. Higgins JPT, Savović J, Page MJ, Elbers RG, JAC S: Chapter 8: Assessing risk of bias in a randomized trial. Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated 2019): Cochrane; 2019.
    1. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ (Clinical research ed) 2019;366:l4898.
    1. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ (Clinical research ed) 2016;355:i4919.
    1. Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol. 2008;61(8):763–769. doi: 10.1016/j.jclinepi.2007.10.007.
    1. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol. 2008;61(1):64–75. doi: 10.1016/j.jclinepi.2007.03.013.
    1. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, et al. Grading quality of evidence and strength of recommendations. BMJ (Clinical research ed) 2004;328(7454):1490. doi: 10.1136/bmj.328.7454.1490.
    1. The opening lecture of Symposium on treating SARS by Traditional Chinese Medicine. Symposium on treating SARS by Traditional Chinese Medicine. In. Edited by China BSAoTCMPsRo; 2003.
    1. Liu X, Zhang M, He L, Li Y. Chinese herbs combined with Western medicine for severe acute respiratory syndrome (SARS) Cochrane Database Syst Rev. 2012;10:CD004882.
    1. Leung PC. The efficacy of Chinese medicine for SARS: a review of Chinese publications after the crisis. Am J Chin Med. 2007;35(4):575–581. doi: 10.1142/S0192415X07005077.
    1. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, Moher D, Tugwell P, Welch V, Kristjansson E, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ (Clinical research ed) 2017;358:j4008. doi: 10.1136/bmj.j4008.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir